Struma ovarii laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S [2]

Overview

Laboratory findings consistent with the diagnosis of struma ovarii include histopathologic studies and elevated CA-125 levels.

Laboratory Findings

Struma ovarii can be diagnosed only based on histopathologic studies. ^[1]
Elevated levels of CA-125 has been reported rarely in approximately only 8-10 of cases so far. ^[2]^[3]
In cases of metastatic struma ovarii post total thyroidectomy along with radioiodine scanning and radioiodine ablation, the thyroglobulin levels must be monitored as a tumor marker, and diagnostic radioiodine scans should be done to screen for residual or recurrent disease. ^[4]
For follow-up as a marker of recurrence, serum thyroglobulin levels and I-131 scan may be used. ^[5]^[6]^[1]
The I-131 scan or thyroglobulin have no aid in the follow-up if thyroidectomy is not performed. ^[7]

References

↑ ^1.0 ^1.1 Sinha NK (2014). “Struma ovarii with elevated ca-125 levels and ascites mimicking advanced ca ovary”. J Clin Diagn Res. 8 (3): 140–1. doi:10.7860/JCDR/2014/8005.4138. PMC 4003614. PMID 24783110.
↑ Mitrou S, Manek S, Kehoe S (2008). “Cystic struma ovarii presenting as pseudo-Meigs’ syndrome with elevated CA125 levels. A case report and review of the literature”. Int. J. Gynecol. Cancer. 18 (2): 372–5. doi:10.1111/j.1525-1438.2007.00998.x. PMID 18334015.
↑ Boselie F, Leeuwenberg E (1985). “Birkhoff revisited: beauty as a function of effect and means”. Am J Psychol. 98 (1): 1–39. PMID 4003614.
↑ McGill JF, Sturgeon C, Angelos P (2009). “Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation”. Endocr Pract. 15 (2): 167–73. doi:10.4158/EP.15.2.167. PMID 19289330.
↑ Volpi E, Ferrero A, Nasi PG, Sismondi P (2003). “Malignant struma ovarii: a case report of laparoscopic management”. Gynecol. Oncol. 90 (1): 191–4. PMID 12821363.
↑ Zekri JM, Manifold IH, Wadsley JC (2006). “Metastatic struma ovarii: late presentation, unusual features and multiple radioactive iodine treatments”. Clin Oncol (R Coll Radiol). 18 (10): 768–72. PMID 17168212.
↑ Balci TA, Kabasakal L (2005). “Is the I-131 whole-body scanning proper for follow-up management of the patients with malignant struma ovarii without performing the thyroidectomy?”. Gynecol. Oncol. 99 (2): 520. doi:10.1016/j.ygyno.2005.04.017. PMID 15963556.

Template:WH Template:WS

[pmid24783110-1] 1.0 ^1.1 Sinha NK (2014). “Struma ovarii with elevated ca-125 levels and ascites mimicking advanced ca ovary”. J Clin Diagn Res. 8 (3): 140–1. doi:10.7860/JCDR/2014/8005.4138. PMC 4003614. PMID 24783110.

[pmid18334015-2] Mitrou S, Manek S, Kehoe S (2008). “Cystic struma ovarii presenting as pseudo-Meigs’ syndrome with elevated CA125 levels. A case report and review of the literature”. Int. J. Gynecol. Cancer. 18 (2): 372–5. doi:10.1111/j.1525-1438.2007.00998.x. PMID 18334015.

[pmid4003614-3] Boselie F, Leeuwenberg E (1985). “Birkhoff revisited: beauty as a function of effect and means”. Am J Psychol. 98 (1): 1–39. PMID 4003614.

[pmid19289330-4] McGill JF, Sturgeon C, Angelos P (2009). “Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation”. Endocr Pract. 15 (2): 167–73. doi:10.4158/EP.15.2.167. PMID 19289330.

[pmid12821363-5] Volpi E, Ferrero A, Nasi PG, Sismondi P (2003). “Malignant struma ovarii: a case report of laparoscopic management”. Gynecol. Oncol. 90 (1): 191–4. PMID 12821363.

[pmid17168212-6] Zekri JM, Manifold IH, Wadsley JC (2006). “Metastatic struma ovarii: late presentation, unusual features and multiple radioactive iodine treatments”. Clin Oncol (R Coll Radiol). 18 (10): 768–72. PMID 17168212.

[pmid15963556-7] Balci TA, Kabasakal L (2005). “Is the I-131 whole-body scanning proper for follow-up management of the patients with malignant struma ovarii without performing the thyroidectomy?”. Gynecol. Oncol. 99 (2): 520. doi:10.1016/j.ygyno.2005.04.017. PMID 15963556.

[1]

[2]

[3]

[4]

[5]

[6]

[7]